Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy (Q46847999)

25 December 2017

title

Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy (English)

1 reference

25 December 2017

author

Thai-Yen Ling

8

1 reference

25 December 2017

Hung-Chih Yang

Hung-Chih Yang

3

0 references

Tung-Hung Su

Tung-Hung Su

1

0 references

Chen-Hua Liu

Chen-Hua Liu

6

0 references

Yung-Ming Jeng

Yung-Ming Jeng

4

0 references

Chun-Jen Liu

Chun-Jen Liu

2

0 references

Chen Pei-jer

Pei-Jer Chen

9

0 references

Ding-Shinn Chen

Ding-Shinn Chen

10

0 references

Jia-Horng Kao

Jia-Horng Kao

11

0 references

Tai-Chung Tseng

7

Tai-Chung Tseng

1 reference

25 December 2017

author name string

Huei-Ru Cheng

5

1 reference

25 December 2017

publication date

5 June 2013

1 reference

25 December 2017

Journal of Gastroenterology

published in

1 reference

25 December 2017

volume

49

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

356-362

1 reference

25 December 2017

Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Correlation of hepatocyte HBsAg expression with virus replication and liver pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Correlation of hepatocyte expression of hepatitis B viral antigens with histological activity and viral titer in chronic hepatitis B virus infection: an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

SERPINE2, an inhibitor of plasminogen activators, is highly expressed in the human endometrium during the secretory phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0840-Z

Cytoplasmic hepatitis B antigen in "ground-glass" hepatocytes of carriers

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23736797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23736797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23736797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00535-013-0840-Z

1 reference

25 December 2017

PubMed ID

23736797

1 reference

25 December 2017